ICTM logo
Adjunctive Rifampicin to Reduce Early mortality from STaphylococcus aureus bacteraemia: a multi-centre, randomised, blinded, placebo controlled trial
Will taking rifampicin as an extra antibiotic help sick people with S. aureus blood infections?
What is this study about?

Staphylococcus aureus (or S. aureus) is a bug that can cause serious infections, including infections of the blood. Doctors use an antibiotic to cure S. aureus but sometimes the infection comes back and sometimes the antibiotic does not succeed.

We want to find out whether or not giving an extra antibiotic, called rifampicin, in addition to the standard antibiotic treatment, will help sick people with S. aureus blood infections.

Who is included?

To join, ARREST participants had to be in hospital and have a blood infection which the doctor thought was caused by S. aureus.

Contact details

When is it taking place?

ARREST opened to recruitment in November 2012. Participants were followed up for 12 weeks. Recruitment closed on 28th October 2016 and follow-up was completed on 18th January 2017.

Where is it taking place?

ARREST took place in hospitals in the UK.

Who is funding the study?

It is funded by the NIHR Health Technology Assessment (HTA) programme, UK.

Further information


Type of study:
Randomised trial
Status:
Closed
Study start date:
26 November 2012

Related Publications

Thwaites, G., Auckland, C., Barlow, G., Cunningham, R., Davies, G., Edgeworth, J., Greig, J., Hopkins, S., Jeyaratnam, D., Jenkins, N., Llewelyn, M., Meisner, S., Nsutebu, E., Planche, T., Read, R.C., Scarborough, M., Soares, M., Tilley, R., Torok, M.E., Williams, J., Wilson, P., Wyllie, S., Walker, A.

Adjunctive rifampicin to reduce early mortality from staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial. Trials. 2012; 13:241-241

Marina, N., Bielack, S., Whelan, J., Smeland, S., Krailo, M, Sydes, M.R., Butterfass-Bahloul, T., Calaminus, G., Bernstein, .

International collaboration is feasible in trials for rare conditions: The EURAMOS Experience. Cancer Treatment and Research. 2010; 152:339-353

Marina, N., Bielack, S., Sydes, M.R., Bernstein, M., Butterfass-Bahloul, Smeland, S., Holliday, A., Whelan, .

International collaboration is feasible in trials for rare conditions: the EURAMOS experience. Journal of Clinical Oncology. 2007; 25:726S, 20501-726S, 20501